Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesHeron Therapeuti

Heron Therapeuti

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.3593 USD -0.01 ( 3.96%)
Last update at 2026-11-11T21:04:00Z
VOLUME
4696720
Market Cap
59.61M

Momentum Score

…

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. Heron Therapeutics, Inc. was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. The company was founded in 1983 and is headquartered in Cary, North Carolina.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.34
Low
0.37
High
52 Week Price Range
0.30
Low
1.57
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Heron Therapeutics is a U.S.-based biopharmaceutical company developing and commercializing therapies in supportive care and acute pain management, with a pipeline reliant on clinical and regulatory progress. Long-term growth drivers include pivotal trial readouts, regulatory approvals and partnerships that could support commercialization and revenue expansion; investors may find the company attractive for its portfolio exposure to unmet needs if development milestones are met.

Key risks include high clinical and regulatory execution risk, reliance on a small number of assets, potential need for additional financing and competitive and reimbursement pressures.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.37
Dividend Yield
-
Revenue TTM
151.18M
Revenue Per Share
0.82
Gross Profit TTM
93.63M
Debt / Equity
9.81
ROE
-2408.88%
Net Debt
111.99M
ROCE
-12.64%
Diluted EPS TTM
-0.19

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -20.20M -13.58M -110.56M -182.02M -220.68M
Net income -20.20M -13.58M -110.56M -134.52M -217.66M
Selling general administrative 54.60M 53.40M 58.48M 37.44M 40.15M
Selling and marketing expenses 49.06M 47.09M 61.34M 82.51M 87.18M
Gross profit 113.56M 105.64M 61.94M 52.80M 40.33M
Reconciled depreciation 2.31M 2.49M 2.98M 2.89M 3.02M
Ebit -20.20M -7.55M -106.69M -177.55M -220.85M
Ebitda -17.88M -5.06M -103.79M -174.66M -217.83M
Depreciation and amortization 2.31M 2.49M 2.90M 2.89M 3.02M
Non operating income net other - - - - -0.45M
Operating income -2.54M -11.53M -110.61M -174.66M -217.83M
Other operating expenses 157.44M 155.81M 237.66M 282.33M 304.17M
Interest expense 9.61M 6.03M 3.87M 2.47M 2.41M
Interest income 1.95M 3.55M 3.36M 1.64M 0.43M
Net interest income -7.66M -2.48M -0.50M -0.84M -1.98M
Income tax expense - - 2.73M -47.51M -3.02M
Total revenue 154.90M 144.28M 127.04M 107.67M 86.35M
Total operating expenses 116.09M 117.17M 172.55M 227.46M 258.15M
Cost of revenue 41.35M 38.65M 65.11M 54.87M 46.02M
Total other income expense net -17.66M -2.05M 0.06M -7.37M -2.85M
Net income from continuing ops -20.20M -13.58M -119.70M -182.02M -220.68M
Net income applicable to common shares - - - -182.02M -220.68M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 255.88M 233.15M 222.51M 250.95M 305.71M
Other current assets 9.10M 17.69M 6.12M 13.96M 12.96M
Total liab 241.54M 266.80M 256.48M 237.38M 228.14M
Total stockholder equity 14.33M -33.65M -33.97M 13.57M 77.57M
Other current liab 87.10M 76.71M 73.37M 76.44M 64.84M
Common stock 1.88M 1.52M 1.50M 1.19M 1.02M
Capital stock 2.93M 1.52M 1.50M 1.19M 1.02M
Retained earnings -1939.79M -1919.59M -1906.01M -1795.45M -1613.43M
Other liab - - - 0.24M -
Other assets - - - 15.71M 17.72M
Cash 28.65M 25.80M 28.68M 15.36M 90.54M
Total current liabilities 96.10M 91.46M 79.69M 82.36M 71.06M
Net debt 111.99M 151.96M 150.95M 142.11M 68.95M
Short term debt - 3.04M 3.08M 2.69M 2.42M
Short long term debt total 140.64M 177.76M 179.63M 157.48M 159.50M
Other stockholder equity 1951.18M 1884.41M 1870.53M 1807.86M 1689.99M
Property plant equipment - - - 29.80M 33.56M
Total current assets 238.07M 209.01M 188.77M 205.44M 254.42M
Net tangible assets - - - 13.57M 77.57M
Short term investments 17.98M 33.48M 51.73M 69.49M 67.04M
Net receivables 89.59M 78.88M 60.14M 52.05M 35.50M
Long term debt 140.64M 174.73M 173.75M 149.28M 149.08M
Inventory 92.75M 53.16M 42.11M 54.57M 48.38M
Accounts payable 8.99M 11.71M 3.24M 3.23M 3.80M
Accumulated other comprehensive income 0.00M 0.01M 0.01M -0.02M -0.01M
Common stock total equity - - - - 1.02M
Retained earnings total equity - - - - -1613.43M
Non currrent assets other 5.41M 6.48M 8.13M 15.71M 17.72M
Non current assets total 17.81M 24.13M 33.73M 45.52M 51.28M
Capital lease obligations 0.00M 3.04M 5.88M 8.19M 10.41M
Long term debt total - - - - 149.08M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 16.23M 18.71M 28.85M -3.32M 35.72M
Change to liabilities - - - -0.58M 3.28M
Total cashflows from investing activities 16.01M 18.71M - -3.32M 32.73M
Net borrowings -12.76M 0.00M - - 148.96M
Total cash from financing activities 14.43M 0.94M 54.11M 75.06M 156.03M
Change to operating activities - - - 12.81M -38.23M
Net income -20.20M -13.58M -110.56M -182.02M -220.68M
Change in cash 2.85M -2.88M 13.31M -75.18M -14.60M
Begin period cash flow 25.80M 28.68M 15.36M 90.54M 105.14M
End period cash flow 28.65M 25.80M 28.68M 15.36M 90.54M
Total cash from operating activities -27.59M -22.53M -58.79M -146.91M -203.35M
Issuance of capital stock 26.17M 0.00M 29.74M 75.14M 0.00M
Depreciation 2.31M 2.49M 2.90M 2.89M 3.02M
Other cashflows from investing activities 0.10M 0.03M - - 0.03M
Change to inventory -31.05M -11.05M 12.46M -6.19M -6.48M
Change to account receivables -10.71M -18.74M -8.09M -16.55M 6.35M
Sale purchase of stock - - - - 7.07M
Other cashflows from financing activities -150.00M 0.94M 48.70M 75.06M 297.93M
Change to netincome - - - 42.53M 48.48M
Capital expenditures 0.32M 1.71M 1.54M 1.82M 3.02M
Change receivables - - - - 6.35M
Cash flows other operating - - - - -8.39M
Cash and cash equivalents changes - - - - -14.60M
Change in working capital -31.88M -27.60M 16.79M -10.51M -35.08M
Stock based compensation 10.34M 12.96M 32.85M 42.98M 46.85M
Other non cash items 11.83M 3.20M 3.62M -0.25M 0.90M
Free cash flow -27.91M -24.23M -60.33M -148.74M -206.38M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
HRTX
Heron Therapeuti		 -0.01
3.96%		 0.36 - 46.95 0.39 10.22 1.10 49.68
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Heron Therapeuti

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. Heron Therapeutics, Inc. was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. The company was founded in 1983 and is headquartered in Cary, North Carolina.

25 Fenton Main Street, Cary, NC, United States, 27511

858 251 4400

https://www.herontx.com

128

Name Title Year Born
Dr. Barry D. Quart Pharm.D. Chairman & CEO 1957
Mr. John W. Poyhonen Pres & Chief Commercial Officer 1960
Mr. David L. Szekeres Exec. VP & COO 1974
Ms. Lisa Peraza VP & Chief Accounting Officer 1977
Ms. Kimberly J. Manhard Exec. VP of Drug Devel. & Director 1960
Mr. Sean T. Ristine Sr. VP of HR 1970
Dr. Thomas B. Ottoboni Ph.D. Chief Scientific Officer and Sr. VP of Pharmaceutical & Translational Sciences 1959
Mr. Michael E. Mathews Sr. VP of Acute Care 1963
Dr. Chris M. Storgard Chief Medical Officer 1966
Mr. Craig Alexander Collard CEO & Director 1966

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…